Physician profile
Mark P Carroll
NPI 1437121597
$5,705.25
in general payments reported to CMS, 2019-2025
49 companies · $601 in 2025
The $601 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $586 · 2021: $1,281 · 2022: $1,120 · 2023: $895 · 2024: $583 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,078.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $948.92 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $741.28 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $506.98 | 2020-2025 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $461.12 | 2019-2023 | Xarelto |
| Esperion Therapeutics, INC. | $367.50 | 2020-2025 | Nexletol |
| Amgen INC. | $367.28 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $203.62 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $184.22 | 2021-2025 | Fasenra, Airsupra |
| Pfizer INC. | $167.05 | 2021-2025 | |
| Astellas Pharma US INC | $141.52 | 2019-2024 | Veozah, Myrbetriq |
| Biohaven Pharmaceutical Holding Company Ltd. | $135.56 | 2022 | |
| Glaxosmithkline, LLC. | $130.06 | 2019-2025 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $112.48 | 2023-2024 | Inspire |
| Merck Sharp & Dohme LLC | $108.36 | 2019-2023 | Pneumovax 23, Vaxelis, Vaxneuvance |
| Ibsa Pharma INC. | $106.63 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.